|
|
 Previous Article | Table of Contents | Next Article 
Idiotype Vaccines for Non-Hodgkin's Lymphoma Induce Polyclonal Immune Responses That Cover Mutated Tumor Idiotypes: Comparison of Different Vaccine Formulations
Clemens B. Caspar,
Shoshana Levy, and
Ronald Levy
From the Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA.
The idiotype (Id) of the Ig expressed on the surface of non-Hodgkin's lymphoma cells is a suitable target for immunotherapy. Indeed, treatment with monoclonal anti-Id antibodies (Abs) can induce long-lasting clinical remissions. However, some of the treated patients relapse with a tumor expressing Ig with point mutations in the idio recognized by the particular monoclonal antibody (MoAb). The alternative approach of active immunization with tumor Id can cure the disease in mice with established tumors and is now being studied in clinical trials. Here, we tested the hypothesis that active immunization with the idiotype would evoke a polyclonal immune response that would cover mutated tumor variants. As a test system, we chose the tumor from a patient who had achieved a complete remission after therapy with anti-Id Ab but subsequently relapsed with a mutated tumor variant no longer binding the treatment Ab. Mice were immunized with proteins and genetic vaccines derived from the original tumor, including (1) Id-keyhole limpet hemocyanin protein, (2) Id single-chain variable fragment (scFv) granulocyte-macrophage colony-stimulating factor (GM-CSF) protein, (3) DNA encoding the Id, and (4) an adenovirus encoding the Id. All immunized mice developed a specific immune response detecting tumor-derived Id proteins from the original tumor and from all tumor variants. We conclude that active immunization with tumor Id can induce a polyclonal immune response and therefore may prevent the escape of mutated tumor variants.
Blood, Vol. 90 No. 9 (November 1), 1997:
pp. 3699-3706
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. Kanter, J. Yang, A. Voloshin, S. Levy, J. R. Swartz, and R. Levy
Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines
Blood,
April 15, 2007;
109(8):
3393 - 3399.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Longo
Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure.
J Natl Cancer Inst,
September 20, 2006;
98(18):
1263 - 1265.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Maloney
Immunotherapy for Non-Hodgkin's Lymphoma: Monoclonal Antibodies and Vaccines
J. Clin. Oncol.,
September 10, 2005;
23(26):
6421 - 6428.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Gitelson, C. Hammond, J. Mena, M. Lorenzo, R. Buckstein, N. L. Berinstein, K. Imrie, and D. E. Spaner
Chronic Lymphocytic Leukemia-reactive T Cells during Disease Progression and after Autologous Tumor Cell Vaccines
Clin. Cancer Res.,
May 1, 2003;
9(5):
1656 - 1665.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. K. Roberts, P. O. Livingston, D. B. Agus, J. Pinilla-Ibarz, A. Zelenetz, and D. A. Scheinberg
Vaccination with CD20 peptides induces a biologically active, specific immune response in mice
Blood,
May 15, 2002;
99(10):
3748 - 3755.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. R. Quinn, C. H. Chan, K. G. Hadlock, S. K. H. Foung, M. Flint, and S. Levy
The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis
Blood,
December 15, 2001;
98(13):
3745 - 3749.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rinaldi, F. Ria, P. Parrella, E. Signori, A. Serra, S. A. Ciafrè, I. Vespignani, M. Lazzari, M. G. Farace, G. Saglio, et al.
Antibodies Elicited by Naked DNA Vaccination against the Complementary-determining Region 3 Hypervariable Region of Immunoglobulin Heavy Chain Idiotypic Determinants of B-lymphoproliferative Disorders Specifically React with Patients' Tumor Cells
Cancer Res.,
February 1, 2001;
61(4):
1555 - 1562.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. Honeychurch, A. L. Tutt, T. Valerius, I. A. F. M. Heijnen, J. G. J. Van de Winkel, and M. J. Glennie
Therapeutic efficacy of Fcgamma RI/CD64-directed bispecific antibodies in B-cell lymphoma
Blood,
November 15, 2000;
96(10):
3544 - 3552.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. M. Aarts, R. J. Bende, E. J. Steenbergen, P. M. Kluin, E. C. M. Ooms, S. T. Pals, and C. J. M. van Noesel
Variable heavy chain gene analysis of follicular lymphomas: correlation between heavy chain isotype expression and somatic mutation load
Blood,
May 1, 2000;
95(9):
2922 - 2929.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. L. Reichardt, C. Y. Okada, A. Liso, C. J. Benike, K. E. Stockerl-Goldstein, E. G. Engleman, K. G. Blume, and R. Levy
Idiotype Vaccination Using Dendritic Cells After Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma---A Feasibility Study
Blood,
April 1, 1999;
93(7):
2411 - 2419.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. McCormick, M. H. Kumagai, K. Hanley, T. H. Turpen, I. Hakim, L. K. Grill, D. Tuse, S. Levy, and R. Levy
Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants
PNAS,
January 19, 1999;
96(2):
703 - 708.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
